http://heart.bmj.com/content/96/9/668.full.html Updated information and services can be found at: The treatment costs and delays to treatment of thrombolysis and angioplasty were estimated. These estimates were then incorporated into an existing model of cost-effectiveness that synthesises evidence from 22 randomised trials to estimate health outcomes measured by quality-adjusted life years (QALYs). Main outcome measures Costs from a health service perspective and outcomes measured as quality adjusted.
Primary angioplasty versus thrombolysis for acute ST-elevation myocardial infarction: an economic analysis of the National Infarct Angioplasty project evidence from a number of trials dating from the early 1990s suggests that primary angioplasty may be more effective in reducing mortality, reinfarction and stroke. 2 However, the benefits from either type of treatment diminish as the time from symptom onset to treatment increases. Therefore, primary angioplasty must be performed in a manner that minimises the additional time to treatment in order to be clinically effective compared with thrombolysis. Furthermore, the requirement for specialist staff and facilities presents practical challenges to providing primary angioplasty cost-effectively.
A recent cost-effectiveness analysis (the 'York model') compared the two treatment options in a UK setting. 3 The analysis was based on metaanalysis of clinical trial data and suggested that primary angioplasty is likely to be considered costeffective provided that the additional time delay associated with primary angioplasty does not exceed an hour. However, the extent to which some of the values used in this analysis apply to NHS practice remains unclear, particularly in relation to costs and time to treatment.
The National Infarct Angioplasty Project (NIAP) was set up as the result of a recommendation from the prime minister's delivery unit in June 2003 that the Department of Health should develop a clear policy for expanding primary angioplasty and draw conclusions about the feasibility of a national roll-out of this service. The secretary of state subsequently announced funding of up to £1 million to carry out a feasibility study, which was used to collect data from a number of angioplasty pilot sites, selected on the basis of their ability to collect the required data and to reflect a range of geographical settings and service delivery types. This initiative provided the opportunity to assess the cost of the initial treatment episode and time delays of primary angioplasty and thrombolysis in the NHS.
We aimed to estimate the cost-effectiveness of services based on comprehensive primary angioplasty versus thrombolytic-based services by further developing the York model with 'real-life' cost and treatment delay estimates derived from NIAP data.
METHODS

Source of data
Ten hospitals providing primary angioplasty became NIAP pilot sites (see supplementary online appendix 2 for details) and collected detailed data on the initial treatment episode and follow up information to 1 year for all patients with STEMI admitted between 1 April 2005 and 31 March 2006. These hospitals varied in the times primary angioplasty was provided (not all offered 24/7 provision during the study period) and whether they had arrangements with hospitals unable to provide angioplasty for patients to be transferred for primary angioplasty. These hospitals provided information on 2083 patients. < An appendix is published online only. To view these files please visit the journal online (http://heart.bmj.com/content/ vol96/issue9).
As part of NIAP, one hospital that did not provide primary angioplasty also collected data for the study period. We supplemented this control site information by obtaining equivalent data for the same time period from four other hospitals that did not provide primary angioplasty for their patients with STEMI. A total of 919 control patients were included.
NHS resource use and cost
The analysis sought to estimate the cost of the initial treatment for patients treated either by thrombolysis or by primary angioplasty from an NHS perspective. The NIAP database provided information on cardiac drugs (including thrombolytic type), consumables (including number, type and make of stent), tests and the length of stay for each patient and similar information was obtained from each of the control sites for thrombolysed patients. It was not possible to obtain detailed information on the small number of patients treated by primary angioplasty in the control hospitals. All drugs were included whether they were administered before arrival at hospital, at the first hospital for transferred patients or at the subsequent primary angioplasty centre. Exercise tests, echocardiography, radionuclide studies and coronary angiography were reported for each patient, although we assumed that every patient undergoing primary angioplasty also received coronary angiography.
A separate survey of 50 primary angioplasties at five NIAP hospitals was used to estimate the mean duration of the procedure, the typical staffing of the catheter laboratory and how this differed according to whether a procedure occurred in or out of usual operating hours.
Patients treated at primary angioplasty centres may be transferred from feeder hospitals, resulting in additional ambulance journeys. These were defined as transfers of patients between non-primary angioplasty hospitals and primary angioplasty hospitals for any reason, and transfers of patients from primary angioplasty hospitals back to other hospitals. Where clinical staff accompanied the ambulance crew, this was recorded.
Subsequent coronary artery bypass grafts (CABG) or percutaneous coronary interventions (PCI) up to 1 year were identified although cost differences estimated using this data were only incorporated into the cost-effectiveness analysis as a sensitivity analysis. The base-case cost-effectiveness estimates are based on the estimated costs from the rates of CABG and PCI found in the clinical trials.
Unit costs for 2006e7 were obtained from national sources where available (see online appendix 3). In the absence of nationally published data on the unit costs of consumables or the operating costs for the catheter laboratories, we surveyed the NIAP hospitals for these items.
Time to treatment
Presentation delay, defined as the time between the first call for professional help and arrival at hospital, was estimated for thrombolysis patients. For all patients, the time between the first call for professional help and treatment (needle for thrombolysis patients, and inflation of balloon for angioplasty patients) was calculated.
Statistical analysis
To estimate the mean treatment cost and associated variance, regression techniques were used with a range of patient covariates to adjust for case mix. Generalised linear multilevel model techniques were used to account for the skewed nature of the cost data and the grouping of patients within individual hospitals. A g distribution with an identity link was employed together with correlated random coefficients for the variables 'no treatment', 'thrombolysis' and 'primary angioplasty'.
Median time to treatment and binomial exact confidence intervals are reported.
The original York model comprises short-term and long-term elements in the comparison of cost-effectiveness between thrombolysis and primary angioplasty. 3 We retained the principal features of the model but made several adaptations. The first of these was to compare primary angioplasty-based services with thrombolysis-based services, where different proportions of both treatments are performed, rather than a comparison of treatment types themselves. The patient characteristics were those of the NIAP population and all costs were updated to 2006e7 values. The short-term element of the model estimates the probability of death, non-fatal myocardial infarction, non-fatal stroke and revascularisations at 6 months according to the type of treatment and the additional time delay associated with primary angioplasty-based on a statistical synthesis of 22 randomised controlled trials. We made adjustments to the calculation of mortality rates for thrombolysis patients, based on pooled trial data, 4 to reflect the effectiveness of thrombolysis as a function of the observed distribution of presentation delay for these patients. We also incorporated the additional time delay associated with primary angioplasty as observed in the pilot year, defined as the difference between the median time to needle for thrombolysed patients and the time to inflation of balloon for primary angioplasty patients, in place of the time delay seen in the clinical trials. The costs up to 6 months are then calculated with treatment costs updated for this analysis.
Long-term costs and benefits are estimated in the second part of the model by extrapolating using the Nottingham Heart Attack Register. The model expresses benefits as quality-adjusted life years (QALYs) by adjusting the weight allocated to the time period the average patient is alive according to the probability of being in each of the health states. Weights were applied to stroke and myocardial infarction based on published literature. Full details of the cost-effectiveness model are available elsewhere. 3 
Sensitivity analyses
The cost-effectiveness model reflects the uncertainty in model inputs using probabilistic sensitivity analysis 5 to present the probability that primary angioplasty is cost-effective for a given cost-effectiveness thresholddhere £20 000 per QALY is used, reflecting the value below which the National Institute for Health and Clinical Excellence would typically consider a technology to be acceptable. 6 In addition, we incorporated coronary events up to 1 year after the initial treatment in place of the trial-based estimates used in the base-case analysis.
RESULTS
Patient characteristics
A total of 3002 patients were included in the analysis, 2083 treated at NIAP hospitals and 919 controls (table 1) .
More patients at NIAP hospitals received primary angioplasty than thrombolysis (67.1% vs 15.8%), whereas in the control hospitals most patients received thrombolysis (72.6% vs 4.2%). The remainder (17.0% and 23.2%, respectively) received no reperfusion therapy. Of the 667 thrombolysis patients from the control sites only 9% had it administered pre-hospital. Overall, patients at the NIAP hospitals were younger, more ethnically diverse, had a higher prevalence of previous coronary heart disease, and a higher prevalence of hypertension, peripheral vascular disease and diabetes.
Time to treatment
Median time from call to needle was shorter than time from call to balloon (CTB) (table 2).
Call to needle time was shortest for patients receiving thrombolysis in the control hospitals (67 min, 95% CI 64 to 69). For patients treated with thrombolysis in the NIAP hospitals this was longer (75 min, 95% CI 68 to 87). The median CTB in the NIAP hospitals was 131 min (95% CI 129 to 135). For patients transferred to a NIAP hospital from a non-primary angioplasty hospital the time from CTB was longer (167 min, 95% CI 159 to 174) compared with those who were taken directly to the primary angioplasty hospital (120 min, 95% CI 115 to 124). Patients who were taken directly to the catheter laboratory once they had arrived at the PCI hospital had a significantly lower median CTB time (123 min, 95% CI 116 to 130) than those who were not taken directly to the catheter laboratory (140 min, 95% CI, 136 vs 145).
Cost of initial treatment episode
Alternative model specifications were compared. Using the deviance as a measure of fit, a g distribution with an identity link was chosen to transform the expected costs. Explanatory variables were only deleted from the model where they were grossly insignificant with t values well below one. A quadratic effect of age on total cost was found to perform better than either using age on its own or the logarithm of age. The results from the preferred specification are reported in table 3.
The coefficients for no reperfusion treatment, thrombolysis and primary angioplasty provide the estimated episode cost across all hospitals according to treatment given, after controlling for other covariates. For patients treated with neither thrombolysis nor primary angioplasty, there was no significant difference between NIAP hospitals and control hospitals and this final version of the model, therefore, does not include any variable to distinguish location for these patients. For patients treated by thrombolysis, the cost was £3509 (95% CI £2202 to £4817) but was higher in NIAP sites by £852 (95% CI £75 to £1628) after controlling for other covariates. For patients treated by primary angioplasty the cost was £5176 (95% CI £4002 to £6350) for those treated within working hours and was higher for patients treated out of hours by £245 (95% CI À£41 to £531).
A number of other patient covariates were included in the analysis. Age was significantly correlated with treatment cost, with minimum costs occurring at approximately 40 years of age. Previous coronary heart disease (any of previous myocardial infarction, angina, PCI or CABG) was positively correlated with treatment cost as were all other comorbidities. Variables with particularly large coefficients were peripheral vascular disease and cerebrovascular disease. The mean cost was lower where patients died before discharge. Finally, although the procedure costs of non-primary angioplasty and CABG were not components of the initial treatment costs calculated here, these did contribute to costs, principally through their impact on length of stay. CABG during the index admission had a large effect (£4630) on the initial treatment cost.
Cost-effectiveness analysis: base case
Results of the cost-effectiveness analysis are shown in table 4. In the base-case analysis, the mean cost of patients treated in NIAP sites was £829 higher and a mean 0.18 additional QALYs were generated. The incremental cost-effectiveness ratio was therefore £4520 and assuming a cost-effectiveness threshold of £20 000 per QALY the probability that NIAP is cost-effective is 0.90. Two issues were explored in the sensitivity analysis: the additional treatment delay associated with primary angioplasty and the rate of revascularisations. For treatment delay we considered the impact of inter-hospital transfer and of emergency department or coronary care unit bypass for primary angioplasty patients. For transferred patients the point estimate in this evaluation was that treatment in a primary angioplasty-based service was dominated by thrombolysis-based caredthat is, it costed £664 more (95% CI À£324 to £1390) and generated 0.085 fewer QALYs (95% CI À0.83 to 0.34). The probability that primary angioplasty-based care was cost-effective for these patients was approximately 0.38 at the £20 000 threshold and did not exceed 0.45 at any threshold.
For patients who were not transferred from another hospital and for those who were admitted directly to the catheter laboratories, the cost-effectiveness of primary angioplasty-based care was marginally improved compared with the base case. For patients who were not admitted directly to the catheter laboratory, and in the scenario where we used observational data to inform the probability of subsequent CABG or angioplasty, the cost-effectiveness of the primary angioplasty-based service deteriorated but remained well below £10 000 per additional QALY gained.
DISCUSSION
Using observational data relating to actual UK NHS practice in 2005e6, this analysis estimates that primary angioplasty is approximately £1700 more expensive to provide than thrombolysis in a standard setting, after adjusting for observed differences between patients. The additional treatment delay associated with primary angioplasty in the NIAP hospitals was slightly in excess of 1 hour but this varied substantially between patients who were transferred from another hospital and patients who were taken directly to the catheter laboratory. Overall, the NIAP hospitals provided a service that would be considered to be cost-effective compared with the thrombolysisbased service offered in control sites. Cost-effectiveness is improved for the subgroup of patients admitted directly to the catheter laboratories. For the subgroup of patients who were transferred from non-primary angioplasty hospitals to a primary angioplasty hospital, the additional treatment delay of 100 min worsens expected outcomes to the extent that thrombolysisbased care is likely to be more effective as well as being less costly.
Strengths and limitations
This analysis draws on detailed observations of resource use in the UK NHS setting to estimate the costs of primary angioplasty and thrombolysis. The analysis reflects actual duration of hospital stay, the specific types of drugs, including thrombolytic agents used, the consumables that were used including stents and drug-eluting stents by type and by manufacturer, whereas previous estimates of cost-effectiveness relied on assumed typical patterns of usage by procedure.
We examine a pragmatic question by comparing systems of care which make use of both primary angioplasty and thrombolysis to differing degrees, rather than comparing individual treatments.
The study has several potential limitations. It was not possible to consider patients who received no reperfusion treatment in the cost-effectiveness analysis, although the cost analysis does suggest that costs for these patients do not differ between the NIAP and control hospitals. It therefore seems unlikely that this limitation would significantly influence the results.
National agreements on staffing for out of hours work have been used in this analysis but this will vary in practice across sites. Current arrangements may not be considered sustainable in the long term, which might increase costs beyond those attributed here.
We do not have detailed information on the cost of primary angioplasty in the control sites where PCI is performed and therefore assume an equal cost to that at the NIAP sites. Given that there are substantial differences in the cost of thrombolytic treatment between the two systems there may also be differences between primary angioplasty patients, although this is not necessarily the case since the main reason for the difference in thrombolysis cost is length of stay.
Observed rates of angiography, PCI and CABG up to 1 year were relatively low in thrombolysed patients. There is evidence that the rate of early angiography has now risen to approximately 60% in these patients in the UK (J Birkhead, personal communication), which may lead to higher costs and improved outcomes that would need to be reflected in updated economic analysis.
Finally, the rate of pre-hospital thrombolysis in the control cohort was relatively low. It could therefore be argued that we did not compare the NIAP hospitals with the best alternative, although we did compare them with a common 'real-world' alternative. If more widespread use of pre-hospital thrombolysis reduced call to needle times in thrombolysis-based practice then the potential effectiveness and cost-effectiveness of primary angioplasty would be reduced. In the CAPTIM trial subgroup analysis, those presenting in the first 2 h of appearance of symptoms who were treated with pre-hospital thrombolysis seemed to have better outcomes than those taken directly for primary PCI. 7 This needs further evaluation and a pre-hospital thrombolysis strategy for the early presenter, combined with mandated rescue or early angiography, is being compared with primary angioplasty in the current Strategic Reperfusion Early After Myocardial Infarction trial.
CONCLUSION
Primary angioplasty-based services that operated in the NHS in England in 2005e6 did so cost-effectively. Service arrangements such as direct catheter laboratory admissions that reduce the primary angioplasty time delay further should be promoted, while particular attention should be given to patients outside the immediate catchment area of a primary angioplasty hospital. To enable primary angioplasty to be given in a timely and thereby effective and cost-effective manner to these patients requires either rapid transfer or alternative arrangements such as ambulance bypass of non-angioplasty centres, both of which will depend on local arrangements and geography. Where this is not feasible, thrombolysis in the local hospital or community may be the more appropriate treatment option.
